These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31081036)

  • 21. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
    Naggie S; Cooper C; Saag M; Workowski K; Ruane P; Towner WJ; Marks K; Luetkemeyer A; Baden RP; Sax PE; Gane E; Santana-Bagur J; Stamm LM; Yang JC; German P; Dvory-Sobol H; Ni L; Pang PS; McHutchison JG; Stedman CA; Morales-Ramirez JO; Bräu N; Jayaweera D; Colson AE; Tebas P; Wong DK; Dieterich D; Sulkowski M;
    N Engl J Med; 2015 Aug; 373(8):705-13. PubMed ID: 26196665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
    Asahina Y; Itoh Y; Ueno Y; Matsuzaki Y; Takikawa Y; Yatsuhashi H; Genda T; Ikeda F; Matsuda T; Dvory-Sobol H; Jiang D; Massetto B; Osinusi AO; Brainard DM; McHutchison JG; Kawada N; Enomoto N
    Liver Int; 2018 Sep; 38(9):1552-1561. PubMed ID: 29297980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.
    Nehra V; Tan EM; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2016 Feb; 52(2):111-7. PubMed ID: 27092340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
    J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
    Sollima S; Antinori S; Torre A; Binda F; Giacomelli A; Milazzo L
    Int J STD AIDS; 2017 Jul; 28(8):838-840. PubMed ID: 28632109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
    Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
    Singh T; Guirguis J; Anthony S; Rivas J; Hanouneh IA; Alkhouri N
    Liver Int; 2016 Jun; 36(6):802-6. PubMed ID: 26824848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
    Walsh CE; Workowski K; Terrault NA; Sax PE; Cohen A; Bowlus CL; Kim AY; Hyland RH; Han B; Wang J; Stamm LM; Brainard DM; McHutchison JG; von Drygalski A; Rhame F; Fried MW; Kouides P; Balba G; Reddy KR
    Haemophilia; 2017 Mar; 23(2):198-206. PubMed ID: 28124511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.
    Jensen CM; Holle LM
    Pharmacotherapy; 2016 May; 36(5):562-74. PubMed ID: 27027412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
    Abergel A; Metivier S; Samuel D; Jiang D; Kersey K; Pang PS; Svarovskaia E; Knox SJ; Loustaud-Ratti V; Asselah T
    Hepatology; 2016 Oct; 64(4):1049-56. PubMed ID: 27351341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection.
    Liu CH; Sun HY; Liu CJ; Sheng WH; Hsieh SM; Lo YC; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1690-1698. PubMed ID: 29665069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    Smith MA; Chan J; Mohammad RA
    Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.
    Chuang WL; Chien RN; Peng CY; Chang TT; Lo GH; Sheen IS; Wang HY; Chen JJ; Yang JC; Knox SJ; Gao B; Garrison KL; Mo H; Pang PS; Hsu YC; Hu TH; Chu CJ; Kao JH
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1323-9. PubMed ID: 26841930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.
    Moon J; Hyland RH; Zhang F; Brainard DM; Lanzkron S; McHutchison JG; Sulkowski M
    Clin Infect Dis; 2017 Sep; 65(5):864-866. PubMed ID: 28505305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
    Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
    Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.